FDA approves La Jolla's distributive shock therapy

La Jolla Pharmaceutical Co. (NASDAQ:LJPC) added $3.92 (14%) to $32.22 in after-hours trading Thursday after FDA approved Giapreza angiotensin II (formerly LJPC-501) to increase blood pressure in adults with septic or other distributive shock.

The company plans to launch the renin-angiotensin system peptide agonist in March, but did not disclose pricing information...